



ASX Announcement

### **Laurence McAllister resigns as Non-Executive Director**

**SYDNEY, August 31, 2022** - Medlab Clinical Limited (ASX:MDC), an Australian Biotech focused on delivery technology to enhance medicines, is announcing today that Laurence McAllister has resigned as a Non-Executive Director of Medlab Clinical. His new interests require him to concentrate on activities in the Northern Hemisphere and this makes it difficult for him to devote effort to Medlab.

Laurence's time at Medlab has facilitated our withdrawal from the retail of nutraceuticals in Australia while maintaining the ability to licence our nutritional products internationally, for this we thank him.

We wish Laurence well in his new endeavours.

Kind Regards,  
Michael Hall, Chairman  
Medlab Clinical Limited

**ENDS**

#### **Authorisation & Additional information**

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

#### **About Medlab Clinical:**

Medlab Clinical LTD (ASX:MDC) is pioneering the development and Commercialisation of a delivery technology, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability.

Medlab's pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies.

Patented lead drug candidate NanaBis has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis may be equally effective in non-cancer neuropathic pain. NanoCelle, the patented delivery platform is wholly owned by Medlab and developed in Medlab's owned OGTR Registered Laboratory.

NanoCelle is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia (Head Office), USA, and the UK.

For more information, please visit [www.medlab.co](http://www.medlab.co)

**Medlab – better medicines, better patient care**